BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 21398070)

  • 1. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.
    Du B; Long Y; Liu H; Chen D; Liu D; Xu Y; Xie X
    Intensive Care Med; 2002 Dec; 28(12):1718-23. PubMed ID: 12447513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae isolated in a rural hospital.
    Basak S; Mallick SK; Bose S
    J Indian Med Assoc; 2009 Dec; 107(12):855-8. PubMed ID: 20509468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms.
    Mody RM; Erwin DP; Summers AM; Carrero HA; Selby EB; Ewell AJ; Moran KA
    Ann Clin Microbiol Antimicrob; 2007 Jun; 6():6. PubMed ID: 17553151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mortality risk factors for bloodstream infections caused by extended-spectrum beta-lactamase-producing microorganisms].
    Ferrández O; Grau S; Saballs P; Luque S; Terradas R; Salas E
    Rev Clin Esp; 2011 Mar; 211(3):119-26. PubMed ID: 21371702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
    Lautenbach E; Patel JB; Bilker WB; Edelstein PH; Fishman NO
    Clin Infect Dis; 2001 Apr; 32(8):1162-71. PubMed ID: 11283805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy.
    Kang CI; Chung DR; Ko KS; Peck KR; Song JH;
    Ann Hematol; 2012 Jan; 91(1):115-21. PubMed ID: 21556875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.
    Shanthi M; Sekar U
    J Assoc Physicians India; 2010 Dec; 58 Suppl():41-4. PubMed ID: 21568008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Antimicrob Agents Chemother; 2012 Jun; 56(6):2888-93. PubMed ID: 22430969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.
    Lee CH; Su LH; Tang YF; Liu JW
    J Antimicrob Chemother; 2006 Nov; 58(5):1074-7. PubMed ID: 16971415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
    Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
    P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and antimicrobial resistance patterns of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated from blood cultures in an Istanbul University Hospital.
    Koksal F; Ak K; Kucukbasmaci O; Samasti M
    Chemotherapy; 2009; 55(4):293-7. PubMed ID: 19521075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.
    Cordery RJ; Roberts CH; Cooper SJ; Bellinghan G; Shetty N
    J Hosp Infect; 2008 Feb; 68(2):108-15. PubMed ID: 18063198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Lo CL; Lee CC; Li CW; Li MC; Hsueh PR; Lee NY; Ko WC
    J Microbiol Immunol Infect; 2017 Jun; 50(3):355-361. PubMed ID: 26423244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Apisarnthanarak A; Kiratisin P; Mundy LM
    Infect Control Hosp Epidemiol; 2008 Jul; 29(7):671-4. PubMed ID: 18624669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.